ANI Pharma (ANIP) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
November 4, 2015 8:13 AM ESTRoth Capital maintained a Buy rating on ANI Pharmaceuticals (NASDAQ: ANIP), and cut the price target to $56.00 (from $60.00), following the company's 3Q15 earnings report. ANIP reported 3Q15 revenues of $20 million, which trailed consensus of $21.4M. The downside appeared to come from non-core branded revenues. Management... More
